Connected Pens for Diabetes Study

Companion Medical, Inc.21 enrolled

Overview

The objective of the study is to evaluate the impact of a wireless smart insulin pen and smartphone-based bolus advisor on clinical and psychosocial outcomes in insulin-treated diabetes mellitus patients after 3 months of use.

The study is a prospective, randomized, controlled treatment design. The study device will be used for multiple daily injection (MDI) therapy of insulin. The participant will interact with the study device in the uncontrolled environment of the participant's daily life. The study protocol is designed to yield meaningful data to determine clinical and psychosocial benefits of using the study device. The study will evaluate the study device as an intervention versus a control group.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetes Mellitus

Interventions

Connected insulin pen and smartphone appDEVICE

The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.

Inactive connected insulin pen without smartphone appDEVICE

The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The participant is ≥ 18 years of age 2. The participant has Type 1 OR Type 2 diabetes and is being treated with intensive insulin therapy via injection for ≥ 3 months. Intensive insulin therapy is defined as at least one long acting insulin dose and two or more short acting insulin doses per day. 3. Glycated hemoglobin (HbA1c) ≥ 7.5%). 4. The participant is a current iPhone user for over 30 days. 5. Participant adjusts meal insulin doses based on carbohydrate content of meals. 6. The participant is fluent in the English language. 7. The participant and the investigator understand participant obligations and agree that the participant is willing and able to complete the study visits. 8. Patients prandial insulin need must be \<30 U per meal. Exclusion Criteria: 1. The participant has been using unblinded CGM for less than 6 months. 2. The participant uses pre-mixed insulin. 3. Current use of a smart insulin pen. 4. Use of sliding scale insulin therapy that determines insulin dosages based exclusively on specific blood glucose results 5. Used systemic oral or inhaled steroids for more than 7 days within the last 3 months 6. Oral anti-diabetic agents, with the exception of metformin 7. Injectable anti-diabetic agents other than insulin 8. The participant is legally blind or has below specified best-corrected vision level. 9. Diagnosed with any clinically significant infectious disease or major organ system disease, such as gastroparesis or renal disease (at Investigator's discretion) 10. The participant is pregnant, lactating, or plans to become pregnant in the next 6 months. 11. The participant is currently participating in another clinical study that may preclude the participant from meeting the obligations of this study. 12. The participant has any additional condition(s) (medical, social, or psychosocial) that in the investigator's opinion would warrant exclusion from the study or prevent the participant from completing or complying with the study requirements.

Locations (1)

Mary & Dick Allen Diabetes Center, Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Outcomes

Primary Outcomes

CGM time in range

Percent CGM time in range (70-180 mg/dL) at 90 days, measured over 14 day period

Time frame: 3 months

Secondary Outcomes

Absolute change in HbA1c

Average change in HbA1c from Baseline to Month 3 compared between groups

Time frame: 3 months

Mean sensor glucose (mg/dL)

Mean sensor glucose will be measured on the final blinded, professional CGM session performed at the end of the 3 month

Time frame: 3 months

Percent CGM time spent in hypoglycemia (70-54 mg/dl, < 54 mg/dL)

Percent of time spent in hypoglycemia from Baseline to Month 3 will be compared between groups

Time frame: 3 months

Percent CGM time spent in hyperglycemic range (>180 mg/dl, >250 mg/dL)

Percent of time spent in hyperglycemia from Baseline to Month 3 will be compared between groups

Time frame: 3 months

Change in patient reported outcomes - ADDQoL

The Audit of Diabetes Dependent Quality of Life (ADDQoL) Questionnaire measures diabetes-specific quality of life. The 19 items measure the impact of diabetes on specific aspects of life and the importance of these aspects of life for quality of life.

Time frame: 3 months

Change in patient reported outcomes - DTSQ

The Diabetes Treatment Satisfaction Questionnaire (DTSQ) measures diabetes treatment satisfaction. The 8 items measure treatment satisfaction and perceived frequency of hyperglycemia and hypoglycemia.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.